Memphasys (ASX:MEM) Common Stock : A$59.43 Mil (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Memphasys Common Stock?

Memphasys's quarterly common stock increased from Dec. 2023 (A$54.94 Mil) to Jun. 2024 (A$57.28 Mil) and increased from Jun. 2024 (A$57.28 Mil) to Dec. 2024 (A$59.43 Mil).

Memphasys's annual common stock increased from Jun. 2022 (A$50.34 Mil) to Jun. 2023 (A$53.42 Mil) and increased from Jun. 2023 (A$53.42 Mil) to Jun. 2024 (A$57.28 Mil).

Memphasys Common Stock Historical Data

The historical data trend for Memphasys's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Memphasys Common Stock Chart

Memphasys Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Common Stock

Get a 7-Day Free Trial

48.70

48.88

50.34

53.42

57.28

Memphasys Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial															53.42	53.42	54.94	57.28	59.43

Memphasys Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Memphasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Memphasys Ltd (ASX:MEM) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Richmond Road, Homebush, Sydney, NSW, AUS, 2140

Website

https://www.memphasys.com

Memphasys Ltd is an Australian-based emerging small-cap reproductive biotechnology company. It develops and commercializes novel reproduction and fertility solutions for humans and animals. Its technology includes Hydrogel and other polymer membrane technology development. The company is developing novel medical devices, diagnostics, and media with applications to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.